Abstract
The treatment of Alzheimer's disease attempts to correct cholinergic deficiency in the brain. In addition to the established, but restricted, efficacy of acetylcholinesterase inhibitors, attempts are being made to develop agents which will stimulate muscarinic receptors directly. This approach is logical and was found efficacious in several animal models of the disease; however none of these agents succeeded in clinical studies. Several reasons might account for this failure, which are discussed, as well as the prospects for the future.
Original language | English |
---|---|
Pages (from-to) | 2259-2267 |
Number of pages | 9 |
Journal | Expert Opinion on Investigational Drugs |
Volume | 9 |
Issue number | 10 |
DOIs | |
State | Published - 2000 |
Keywords
- Alzheimer's disease
- Cholinesterase inhibitors
- Cholinomimetics
- Muscarinic agonists
- Therapy